FR2267783A1 - 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis - Google Patents

3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis

Info

Publication number
FR2267783A1
FR2267783A1 FR7414126A FR7414126A FR2267783A1 FR 2267783 A1 FR2267783 A1 FR 2267783A1 FR 7414126 A FR7414126 A FR 7414126A FR 7414126 A FR7414126 A FR 7414126A FR 2267783 A1 FR2267783 A1 FR 2267783A1
Authority
FR
France
Prior art keywords
pyridine methanol
dyslipemia
atheromatosis
cerebral
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7414126A
Other languages
French (fr)
Other versions
FR2267783B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre SA
Original Assignee
Pierre Fabre SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre SA filed Critical Pierre Fabre SA
Priority to FR7414126A priority Critical patent/FR2267783A1/en
Publication of FR2267783A1 publication Critical patent/FR2267783A1/en
Application granted granted Critical
Publication of FR2267783B1 publication Critical patent/FR2267783B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

3-Pyridine methanol theophyline acetate (I) of formula: is new and may be prep. by dissolving equimolar amounts of 3-pyridine methanol and theophylline acetic acid in water, and evaporating to dryness, the yield being quantitative. (I) may be formulated for oral, parenteral or rectal administration, optionally mixed with diuretics, cardiotonics, sedatives, heparin, anti-aggregants, antispasmodics, or vitamins. Patients suffering from chronic cerebral circulatory insufficiency have been treated with 500-1000 mg per dose for 21 days. Best results were obtained at a daily dosage of 2 g. Intravenous administration of 10 ampoules/day, each contg. 500 mg (I), has also been used.
FR7414126A 1974-04-22 1974-04-22 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis Granted FR2267783A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7414126A FR2267783A1 (en) 1974-04-22 1974-04-22 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7414126A FR2267783A1 (en) 1974-04-22 1974-04-22 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis

Publications (2)

Publication Number Publication Date
FR2267783A1 true FR2267783A1 (en) 1975-11-14
FR2267783B1 FR2267783B1 (en) 1978-07-21

Family

ID=9138021

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7414126A Granted FR2267783A1 (en) 1974-04-22 1974-04-22 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis

Country Status (1)

Country Link
FR (1) FR2267783A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639541A1 (en) * 1988-11-29 1990-06-01 Fabre Pierre Cosmetique TOPICAL SLIMMERS CONTAINING CARBOXYLIC CARBOXYLIC DERIVATIVES DERIVED FROM ORGANIC BASES AND PREPARATIONS USEFUL IN THE TREATMENT OF CELLULITE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2639541A1 (en) * 1988-11-29 1990-06-01 Fabre Pierre Cosmetique TOPICAL SLIMMERS CONTAINING CARBOXYLIC CARBOXYLIC DERIVATIVES DERIVED FROM ORGANIC BASES AND PREPARATIONS USEFUL IN THE TREATMENT OF CELLULITE
EP0371874A1 (en) * 1988-11-29 1990-06-06 Pierre Fabre Cosmetique Topical slimming agents containing caffein carboxylic acids neutralised by organic bases, and preparations for the treatment of cellulitis

Also Published As

Publication number Publication date
FR2267783B1 (en) 1978-07-21

Similar Documents

Publication Publication Date Title
Tarail Relation of abnormalities in concentration of serum potassium to electrocardiographic disturbances
ES471981A1 (en) Quinazoline derivatives, process for their preparation, pharmaceutical preparations and their preparation.
IE40858B1 (en) New benzimidazole derivatives,their preparation,and their use in affecting gastric acid secretion
FR2439194A1 (en) DIBENZOTHIEPINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
FR2367750A1 (en) ACID
FR2267783A1 (en) 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis
Marinow Diabetes in chronic schizophrenia.
US3574831A (en) Therapeutic heparin-sodium taurocholate compositions
GB1144246A (en) Improvements in or relating to reduction products of hydroxyisoquinolines
Raska The production of experimental pellagra by adenine
Takagi et al. The therapeutic effect of FM100, a fraction of licorice root, on acetic acid ulcer in rats
Goodman et al. Inhibition of human tumour clonogenicity by chlorambucil and its metabolites.
BE901489A (en) METHOD FOR THE TREATMENT OF HEART DISEASE.
FR2260330A1 (en) Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index
SU1271520A1 (en) Immunostimulator
FR2414507A1 (en) Trans or 21-epi-eburnamonine - for treatment of cerebral oxygenation insufficiency has superior therapeutic index to vincamine and vincamone
Connolly Arrhythmias associated with digitalis therapy
Robbins et al. A new mercurial diuretic
JPS5811856B2 (en) 2 4-bis (2'-acetoxybenzamide)
Riska et al. Optimal PAS dosage
SU1437024A1 (en) Method of treatment of acute renal insufficiency
SU1646551A1 (en) Method for prophylaxis of alcoholism relapses
SU1171035A1 (en) Method of curing syphilis
SU1584951A1 (en) Method of treatment of mycosis fungoides
FR2434814A1 (en) BROMO-2 ERGOSININE AND ITS SALTS OF ADDITION OF USEFUL ACIDS AS MEDICAMENTS AND A PROCESS FOR THEIR PREPARATION

Legal Events

Date Code Title Description
ST Notification of lapse